The main end-point
of our group is the development of mice xenograft models of breast
cancer as a platform for the development of new biomarkers with utility
in breast cancer treatment. Therefore we develop programs with the
double aim of testing new treatments on breast cancer and finding
new biomarkers of efficacy of these treatments with potential value
for their translation into clinical trials in patients.
As a first flag-ship project of this group we are investigating molecular
markers undergoing early regulation by hormonal treatments in hormone-sensitive
breast cancer. These markers will be developed with a view to their
use in the clinical setting as early predictors of clinical response
to treatment. This is the continuation of the research initiated by
the principal investigator of this group at the Royal Marsden Hospital
/ Institute of Cancer Research in London under professor Mitch Dowsett.
In this institution the PI developed a study for the molecular characterization
of the early gene regulation following treatment with aromatase inhibitors
in early breast cancer. As a result of this study some potential biomarkers
were selected for their individual investigation.
As a group we are
tightly linked to the research developed by Dr. Miguel Angel Genestar
Pujana with whom we cooperate in projects
aiming to find genes with a potential value as modulators, predictors
or prognosticators in breast cancer.
|
